QualityStocks News - Power of the Dream Ventures Subsidiary Partners with German Cancer Research Center to Tackle HPV Infection

Collaboration will initiate preclinical research aimed at developing a treatment for Human Papilloma Virus after infection has occurred

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
We believe that it will provide a breakthrough in cancer immunotherapy.

Scottsdale, Arizona (PRWEB) October 13, 2012

QualityStocks would like to highlight Power of the Dream Ventures, Inc., a publicly traded company that operates as a development stage technology holding company, focused on acquiring, developing, licensing, co-developing, and commercializing technologies that originate exclusively in Hungary that are in prototype stage based on existing patents; in prototype stage prior to patenting; existing products that require expansion capital to commercialize; and emerging science and high-technology research projects that require help in patenting, developing the product and marketing, university spin-off technologies, and ideas from the very early stage that represent ‘disruptive technologies’.

In the company’s news yesterday,

Genetic Immunity, a wholly owned subsidiary of Power of the Dream Ventures, has inked an agreement with DKFZ (German Cancer Research Center, Heidelberg, Germany) to develop a DNA-based vaccine for the treatment of Human Papilloma Virus (HPV) infection that causes cervical and other cancers. The companies are addressing a gap in the market between vaccines such as Cervarix and Gardasil, which have no therapeutic effect on HPV-related diseases, and the need for a product to treat diseases or conditions caused by HPV.

“There is a huge unmet medical need for such cancer vaccine, because vaccines we have developed earlier do not provide protection against cancer when used for treatment of existing conditions caused by HPV. Our goal is to provide protection against cancer for patients after the onset of sexual activity, after they might be exposed to HPV,” Dr. Julianna Lisziewicz, CEO of Genetic Immunity stated in the press release.

The Division of Genome Modifications and Carcinogenesis will commence a preclinical research program to evaluate the therapeutic efficacy of the DKFZ’s HPV-specific plasmid DNA using Genetic Immunity’s nanomedicine formulation and Langerhans cell-targeting administration technologies.

The newly formed collaboration will use Genetic Immunity’s clinically proven technology, as demonstrated in clinical trials of DermaVir as an immunotherapy for the cure of HIV, in its research. The collaboration will test whether HPV-specific memory T cells induced by Genetic Immunity’s nanomedicine products could protect against cancer after infection has already occurred.

“We found that Genetic Immunity technology is unique to target the vaccine DNA into the nucleus of the Langerhans cells. We believe that it will provide a breakthrough in cancer immunotherapy. We pioneered HPV prophylactic vaccines with new innovations and we would like to expand this tradition to therapeutic setting,” said DKFZ’s Dr. Prof. Gissmann, who will initiate the preclinical research program.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for The QualityStocks Daily Newsletter, please visit http://www.QualityStocks.net

To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage

To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks

Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.


Contact